(Q45966480)

18 December 2017

title

Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals. (English)

1 reference

18 December 2017

0 references

1 reference

Elizabeth C TePas

1

1 reference

18 December 2017

Elisabeth G Hoyte

series ordinal

2

1 reference

18 December 2017

Jennifer J McIntire

series ordinal

3

1 reference

18 December 2017

Dale T Umetsu

series ordinal

4

1 reference

18 December 2017

publication date

1 January 2004

1 reference

18 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

18 December 2017

volume

92

1 reference

18 December 2017

issue

1

1 reference

18 December 2017

page(s)

25-31

1 reference

18 December 2017

The burden of asthma with specific reference to the United States

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Long-term clinical efficacy of grass-pollen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Microencapsulation: the future of oral immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Oral tolerance for the treatment of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Suppression of asthma-like responses in different mouse strains by oral tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Approach to the patient with a history of adverse reactions to aspirin or NSAIDs: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Cytokine production by peripheral blood mononuclear cells following birch-pollen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-gamma and IL-4 expression by circulating T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Asthma: an epidemic of dysregulated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Oral tolerance in the treatment of inflammatory autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Induction of Oral Tolerance in the Primed Immune System: Influence of Antigen Persistence and Adjuvant Form

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Effects of insulin in relatives of patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Different methods of local allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

Oral and sublingual immunotherapy in paediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961706-1

7 January 2021

10.1016/S1081-1206(10)61706-1

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017